Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure

Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure

Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type IIA-Fc fusion protein (ActRIIA-Fc) was found previously to be efficacious in experimental and human pulmonary arterial hypertension (PAH). Here w...

Full description

Bibliographic Details
Main Authors: Sachindra R. Joshi, Elif Karaca Atabay, Jun Liu, Yan Ding, Steven D. Briscoe, Mark J. Alexander, Patrick Andre, Ravindra Kumar, Gang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Group 2 pulmonary hypertension (PH)
pulmonary arterial hypertension
heart failure with preserved ejection fraction
heart failure with reduced ejection fraction
ActRIIA-Fc
activin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1064290/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1064290/full

Similar Items